Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00800618 · ClinicalTrials.gov registry record · Phase 1
A Study To Investigate How The Body Handles Multiple Doses Of PF-0243873 And To Investigate The Effect Of PF-02413873 On Sex Hormone Levels In Healthy Young Women
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT00800618 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 42 participants.
The verdict
NCT00800618, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
The study will investigate how well multiple doses of PF-02413873 are tolerated by healthy young women, how the body handles multiple doses of PF-02413873 and which effect PF-02413873 has on sex hormones in healthy young women
Interventions
- DRUG PF-02413873 100 mg QD
- DRUG PF-02413873 1500 mg QD
- DRUG PF-02413873 20 mg QD
- DRUG PF-02413873 500 mg QD
- DRUG PF-02413873 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2008-11 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00800618
The ClinicalTrials.gov registry entry for NCT00800618 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which PF-02413873 100 mg QD is the first listed.
NCT00800618 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00800618 about?
NCT00800618 is a clinical study titled "A Study To Investigate How The Body Handles Multiple Doses Of PF-0243873 And To Investigate The Effect Of PF-02413873 On Sex Hormone Levels In Healthy Young Women". The study will investigate how well multiple doses of PF-02413873 are tolerated by healthy young women, how the body handles multiple doses of PF-02413873 and which effect PF-02413873 has on sex hormones in healthy young women
What is the current status of trial NCT00800618?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2008-11. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00800618?
The interventions under investigation include: PF-02413873 100 mg QD (DRUG), PF-02413873 1500 mg QD (DRUG), PF-02413873 20 mg QD (DRUG), PF-02413873 500 mg QD (DRUG), PF-02413873 Placebo (DRUG).
Who is sponsoring clinical trial NCT00800618?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.